Skip to main content
. Author manuscript; available in PMC: 2005 Oct 26.
Published in final edited form as: Kidney Int. 2005 May;67(5):1731–1738. doi: 10.1111/j.1523-1755.2005.00270.x

Table I.

Binding affinity and Bmax of AT2 receptor orthologues

[Sar1,Ile8]Ang II, (Ki, nM)
CGP42112A, (Ki, nM)
PD123319, (Ki, nM)
Bmax, (pmol/mg)
Control DTT (5mM) -fold Control DTT (5mM) -fold Control DTT (5mM) -fold Control DTT (5mM) -fold
rbAT2 0.89±0.15 0.09±0.02 9.89 0.61±0.13 0.07±0.01 8.71 17.7±2.2 2.4±0.43 7.38 4.05±0.35 0.85±0.38 4.765
rAT2 0.82±0.14 0.08±0.01 10.3 0.65±0.11 0.07±0.01 9.29 17.2±2.5 2.1±0.37 8.19 4.11±0.32 3.95±0.34 1.041
mAT2 0.83±0.12 0.08±0.01 10.4 0.63±0.10 0.08±0.01 7.88 18.4±2.8 2.5±0.31 7.36 4.08±0.36 4.09±0.41 0.998
hAT2 0.87±0.11 0.09±0.01 9.67 0.57±0.09 0.07±0.01 8.14 16.7±2.6 2.3±0.36 7.26 3.93±0.33 3.91±0.37 0.995
rbAT2N 2.98±0.76 0.11±0.02 27.1 0.69±0.12 0.08±0.01 8.63 17.6±2.3 2.3±0.38 7.69 3.78±0.32 0.62±0.35 6.096

Cell membranes were pre-treated with and without 5mM DTT at 22°C for 20 minutes. Here rbAT2, rAT2, mAT2, and hAT2 represent rabbit, rat, mouse, and human AT2 receptor orthologues, respectively. The rbAT2N is a rbAT2 mutant with deletion of the first 33 amino acids. This mutant is very similar to the wild type rbAT2 except for a reduced binding affinity (3.3 fold) for [Sar1,Ile8]Ang II in the absence of DTT treatment. Data represent results of three or more experiments of binding isotherms followed by Scatchard analysis. Results are presented as mean ± s.e.m.